BridgeBio Pharma Inc (NASDAQ:BBIO)

6.74
Delayed Data
As of May 16
 +0.12 / +1.81%
Today’s Change
4.98
Today|||52-Week Range
65.33
-59.59%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$977.0M

Company Description

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Contact Information

BridgeBio Pharma, Inc.
421 Kipling Street
Palo Alto California 94301
P:(650) 391-9740
Investor Relations:

Employees

Shareholders

Individual stakeholders53.85%
Other institutional49.58%
Mutual fund holders22.36%

Top Executives

Neil KumarChief Executive Officer & Director
Christine E. SiuChief Operating Officer
Brian C. StephensonChief Financial Officer & Secretary
Uma SinhaChief Scientific Officer
Richard H. SchellerDirector, Chairman-Research & Development